Below are the most recent publications written about "Chemoradiotherapy" by people in Profiles.
-
Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025 Feb; 193:119-129.
-
Mayadev J, Zamarin D, Deng W, Lankes HA, Pesci G, Kim H, Chino JP, Banbury B, Sherry N, Sharon E, Ghamande SA, Ferguson C, Mell L, Holman L, Mathews C, O'Malley D, Olawaiye A, Hopp E, Leath C, Copeland L, Mannel R, O'Cearbhaill R, Aghajanian C, Schilder RJ. Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553.
-
Nadeem MS, Ali U, Khan A, Wajid I, Riaz O, Azeem MT. Response of various histological types of locally advanced rectal cancer to neoadjuvant multimodality therapy. J Pak Med Assoc. 2024 Jul; 74(7):1240-1244.
-
DesJarlais AM, Miller R, Ali AS, Niazi MZ, Cappelli L, Glass J, Farrell CJ, Shi W. Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment. Chin Clin Oncol. 2023 Dec; 12(6):69.
-
Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 10; 11(5):40.
-
Benedict PA, Kravietz A, Yang J, Achlatis E, Doyle C, Johnson AM, Dion GR, Amin MR. Longitudinal Effects of Base of Tongue Concurrent Chemoradiation Therapy in a Pre-Clinical Model. Laryngoscope. 2023 06; 133(6):1455-1461.
-
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 02 17; 107(3):776-787.
-
Bossi P, Trama A, Bernasconi A, Grisanti S, Mohamad I, Galiana IL, Ozyar E, Franco P, Vecchio S, Bonomo P, Cirauqui BC, El-Sherify M, Ursino S, Argiris A, Pan J, Wittekindt C, D'Angelo E, Costa L, Buglione M, Johnson J, Airoldi M, Mesia R, Resteghini C, Licitra L, Orlandi E. Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. Eur J Cancer. 2021 12; 159:194-204.
-
Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 02; 26(2):376-386.
-
Kozono DE, Stinchcombe TE, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Chen X, Sun Z, Nuthalapati S, Rosenwinkel L, Johnson EF, Bach BA, Luo Y, Vokes EE. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.